US Patent

US12275715 — Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Method of Use · Assigned to Forma Therapeutics Inc · Expires 2035-09-18 · 9y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a class of compounds that inhibit mutant isocitrate dehydrogenase proteins, useful in treating cell-proliferation disorders and cancers.

USPTO Abstract

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W 1 , W 2 , W 3 , R 1 -R 6 , and R 9 are described herein.

Drugs covered by this patent

Rezlidhia (OLUTASIDENIB) · Rigel Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3684`	—	Rezlidhia

Patent Metadata

Patent number: US12275715
Jurisdiction: US
Classification: Method of Use
Expires: 2035-09-18
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Forma Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.